The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Quinolone-Mediated Bacterial Death
Open accessAbstract
The fluoroquinolones are broad-spectrum antibacterial agents that are becoming increasingly popular as bacterial resistance erodes the effectiveness of other agents (fluoroquinolone sales accounted for 18% of the antibacterial market in 2006) (41). One of the attractive features of the quinolones is their ability to kill bacteria rapidly, an ability that differs widely among the various derivatives. For example, quinolones differ in rate and extent of killing, in the need for aerobic metabolism to kill cells, and in the effect of protein synthesis inhibitors on quinolone lethality. Understanding the mechanisms underlying these differences could lead to new ways for identifying the most bactericidal quinolone derivatives. Before describing the types of damage caused by the quinolones, it is useful to define lethal activity. Operationally, it is the ability of drug treatment to reduce the number of viable cells, usually measured as CFU on drug-free agar after treatment. This assay is distinct from measurements that detect inhibition of growth (e.g., MIC), since with the latter bacteria are exposed to drug throughout the measurement. The distinction between killing and blocking growth is important because it allows susceptibility determinations to be related to particular biological processes. For example, inhibition of growth is typically reversed by the removal of drug, while cell death is not. Thus, biochemical events associated with blocking growth should be readily reversible, while those responsible for cell death should be difficult to reverse. Reversibility can be used to distinguish among quinolone derivatives and assign functions to particular aspects of drug structure. Moreover, protective functions, such as repair and stress responses, can be distinguished by whether their absence affects inhibition of growth, killing, or both. The intracellular targets of the quinolones are two DNA topoisomerases: gyrase and topoisomerase IV. Gyrase tends to be the primary target in gram-negative bacteria, while topoisomerase IV is preferentially inhibited by most quinolones in gram-positive organisms (28). Both enzymes use a double-strand DNA passage mechanism, and it is likely that quinolone biochemistry is similar for both. However, physiological differences between the enzymes exist, some of which may bear on quinolone lethality. In the present minireview we consider cell death through a two-part “poison” hypothesis in which the quinolones form reversible drug-topoisomerase-DNA complexes that subsequently lead to several types of irreversible (lethal) damage. Other consequences of quinolone treatment, such as depletion of gyrase and topoisomerase IV activity, are probably less immediate (42). To provide a framework for considering quinolone lethality, we begin by briefly describing the drug-topoisomerase-DNA complexes. Readers interested in a more comprehensive discussion of quinolones are referred to a previously published work (28).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wayne, L. G., & Hayes, L. G. (1996) · Infection and Immunity · doi:10.1128/iai.64.6.2062-2069.1996 · Cited by 1,141
Prokaryotic toxin–antitoxin stress response loci
Gerdes, K., Christensen, S. K., & Løbner-Olesen, A. (2005) · Nature Reviews Microbiology · doi:10.1038/nrmicro1147 · Cited by 1,033
Hsiang, Y. H., Lihou, M. G., & Liu, L. F. (1989) · PubMed · Cited by 1,028
Nalidixic acid resistance: A second genetic character involved in DNA gyrase activity
Gellert, M., Mizuuchi, K., O'Dea, M. H., Itoh, T., & Tomizawa, J.-I. (1977) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.74.11.4772 · Cited by 833
Sugino, A., Peebles, C. L., Kreuzer, K. N., & Cozzarelli, N. R. (1977) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.74.11.4767 · Cited by 784
Quinolone resistance-determining region in the DNA gyrase gyrB gene of Escherichia coli
Yoshida, H., Bogaki, M., Nakamura, M., Yamanaka, L. M., & Nakamura, S. (1991) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.35.8.1647 · Cited by 777
On the structure of the folded chromosome of Escherichia coli
Worcel, A., & Burgi, E. (1972) · Journal of Molecular Biology · doi:10.1016/0022-2836(72)90342-7 · Cited by 643
Quinolone resistance-determining region in the DNA gyrase gyrA gene of Escherichia coli
Yoshida, H., Bogaki, M., Nakamura, M., & Nakamura, S. (1990) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.34.6.1271 · Cited by 570
Crystal structure of the breakage–reunion domain of DNA gyrase
Cabral, J. H. M., Jackson, A. P., Smith, C. V., Shikotra, N., Maxwell, A., & Liddington, R. C. (1997) · Nature · doi:10.1038/42294 · Cited by 456
Topoisomerase IV is a target of quinolones in Escherichia coli.
Khodursky, A. B., Zechiedrich, E. L., & Cozzarelli, N. R. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.25.11801 · Cited by 378
Cited by
How antibiotics kill bacteria: from targets to networks
Kohanski, M. A., Dwyer, D. J., & Collins, J. J. (2010) · Nature Reviews Microbiology · doi:10.1038/nrmicro2333 · Cited by 2,258
Mechanism of Quinolone Action and Resistance
Aldred, K. J., Kerns, R. J., & Osheroff, N. (2014) · Biochemistry · doi:10.1021/bi5000564 · Cited by 1,282
Self-citationFluoroquinolone resistance: mechanisms, impact on bacteria, and role in evolutionary success
Redgrave, L. S., Sutton, S. B., Webber, M. A., & Piddock, L. J. V. (2014) · Trends in Microbiology · doi:10.1016/j.tim.2014.04.007 · Cited by 1,008
Plasmid-Mediated Quinolone Resistance: a Multifaceted Threat
Strahilevitz, J., Jacoby, G. A., Hooper, D. C., & Robicsek, A. (2009) · Clinical Microbiology Reviews · doi:10.1128/cmr.00016-09 · Cited by 928
Pham, T. D. M., Ziora, Z. M., & Blaskovich, M. A. T. (2019) · MedChemComm · doi:10.1039/c9md00120d · Cited by 785
Ciprofloxacin Causes Persister Formation by Inducing the TisB toxin in Escherichia coli
Dörr, T., Vulić, M., & Lewis, K. (2010) · PLoS Biology · doi:10.1371/journal.pbio.1000317 · Cited by 782
Phenotypic Landscape of a Bacterial Cell
Nichols, R. J., Sen, S., Choo, Y. J., Beltrao, P., Zietek, M., Chaba, R., Lee, S., Kazmierczak, K. M., Lee, K. J., Wong, A., et al. (2011) · Cell · doi:10.1016/j.cell.2010.11.052 · Cited by 713
Dheda, K., Gumbo, T., Maartens, G., Dooley, K. E., McNerney, R., Murray, M., Furin, J., Nardell, E. A., London, L., Lessem, E., et al. (2017) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(17)30079-6 · Cited by 684
Nanoparticles: Alternatives Against Drug-Resistant Pathogenic Microbes
Rudramurthy, G., Swamy, M., Sinniah, U., & Ghasemzadeh, A. (2016) · Molecules · doi:10.3390/molecules21070836 · Cited by 556
Topoisomerase Inhibitors: Fluoroquinolone Mechanisms of Action and Resistance
Hooper, D. C., & Jacoby, G. A. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a025320 · Cited by 553
SOS Response Induces Persistence to Fluoroquinolones in Escherichia coli
Dörr, T., Lewis, K., & Vulić, M. (2009) · PLoS Genetics · doi:10.1371/journal.pgen.1000760 · Cited by 534
Role of reactive oxygen species in antibiotic action and resistance
Dwyer, D. J., Kohanski, M. A., & Collins, J. J. (2009) · Current Opinion in Microbiology · doi:10.1016/j.mib.2009.06.018 · Cited by 484
Plasmid-Mediated Quinolone Resistance
Jacoby, G. A., Strahilevitz, J., & Hooper, D. C. (2014) · Microbiology Spectrum · doi:10.1128/microbiolspec.plas-0006-2013 · Cited by 479
Quinolones: Mechanism, Lethality and Their Contributions to Antibiotic Resistance
Bush, N. G., Diez-Santos, I., Abbott, L. R., & Maxwell, A. (2020) · Molecules · doi:10.3390/molecules25235662 · Cited by 413
Global Fluoroquinolone Resistance Epidemiology and Implictions for Clinical Use
Dalhoff, A. (2012) · Interdisciplinary Perspectives on Infectious Diseases · doi:10.1155/2012/976273 · Cited by 354
The Normalcy of Dormancy: Common Themes in Microbial Quiescence
Rittershaus, E. S. C., Baek, S.-H., & Sassetti, C. M. (2013) · Cell Host & Microbe · doi:10.1016/j.chom.2013.05.012 · Cited by 340
Targeting DnaN for tuberculosis therapy using novel griselimycins
Kling, A., Lukat, P., Almeida, D. V., Bauer, A., Fontaine, E., Sordello, S., Zaburannyi, N., Herrmann, J., Wenzel, S. C., König, C., et al. (2015) · Science · doi:10.1126/science.aaa4690 · Cited by 316
Bacterial persisters: molecular mechanisms and therapeutic development
Niu, H., Gu, J., & Zhang, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01866-5 · Cited by 310
Proximate and ultimate causes of the bactericidal action of antibiotics
Baquero, F., & Levin, B. R. (2021) · Nature Reviews Microbiology · doi:10.1038/s41579-020-00443-1 · Cited by 307
Structural insight into the quinolone–DNA cleavage complex of type IIA topoisomerases
Laponogov, I., Sohi, M. K., Veselkov, D. A., Pan, X.-S., Sawhney, R., Thompson, A. W., McAuley, K. E., Fisher, L. M., & Sanderson, M. R. (2009) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1604 · Cited by 304
Antibiotics and Bacterial Resistance—A Short Story of an Endless Arms Race
Baran, A., Kwiatkowska, A., & Potocki, L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065777 · Cited by 300
Li, H., Zhou, X., Huang, Y., Liao, B., Cheng, L., & Ren, B. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.622534 · Cited by 284
Contemporary Challenges in the Design of Topoisomerase II Inhibitors for Cancer Chemotherapy
Bailly, C. (2012) · Chemical Reviews · doi:10.1021/cr200325f · Cited by 288
Nonoptimal microbial response to antibiotics underlies suppressive drug interactions
Bollenbach, T., Quan, S., Chait, R., & Kishony, R. (2009) · Cell · doi:10.1016/j.cell.2009.10.025 · Cited by 227
Czatzkowska, M., Harnisz, M., Korzeniewska, E., & Koniuszewska, I. (2020) · Energy Science & Engineering · doi:10.1002/ese3.609 · Cited by 149
de Wet, T. J., Winkler, K. R., Mhlanga, M., Mizrahi, V., & Warner, D. F. (2020) · eLife · doi:10.7554/elife.60083 · Cited by 79
Type II topoisomerases--inhibitors, repair mechanisms and mutations
Heisig, P. (2009) · Mutagenesis · doi:10.1093/mutage/gep035 · Cited by 63
Metadata
- Authors
- Drlica, K., Malik, M., Kerns, R. J., & Zhao, X.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2008-02
- Volume
- 52
- Issue
- 2
- Pages
- 385-392
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2007464877
- Cited by
- 570
- References
- 56
- FWCI
- 9.38
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.